PriceTargets.com logo

Vaxcyte - PCVX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $145.71
  • Forecasted Upside: 68.40%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$86.53 As of 12/20/2024 06:31 PM ET
▲ +0.32 (0.37%)

This chart shows the closing price for PCVX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vaxcyte Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PCVX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PCVX

Analyst Price Target is $145.71
▲ +68.40% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Vaxcyte in the last 3 months. The average price target is $145.71, with a high forecast of $163.00 and a low forecast of $129.00. The average price target represents a 68.40% upside from the last price of $86.53.

This chart shows the closing price for PCVX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Vaxcyte. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/20/2024The Goldman Sachs GroupInitiated CoverageBuy$135.00
11/6/2024Cantor FitzgeraldReiterated RatingOverweight
11/6/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$140.00 ➝ $140.00
9/10/2024MizuhoBoost TargetOutperform ➝ Outperform$113.00 ➝ $163.00
9/4/2024Bank of AmericaBoost TargetBuy ➝ Buy$101.00 ➝ $140.00
9/3/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$108.00 ➝ $129.00
9/3/2024Leerink PartnersBoost TargetOutperform ➝ Outperform$106.00 ➝ $153.00
9/3/2024BTIG ResearchBoost TargetBuy ➝ Buy$98.00 ➝ $160.00
9/3/2024Needham & Company LLCBoost TargetBuy ➝ Buy$95.00 ➝ $140.00
8/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$95.00 ➝ $95.00
6/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$95.00 ➝ $95.00
6/20/2024Cantor FitzgeraldReiterated RatingOverweight
5/9/2024Cantor FitzgeraldReiterated RatingOverweight
5/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$95.00
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$95.00
2/28/2024Needham & Company LLCBoost TargetBuy ➝ Buy$73.00 ➝ $95.00
1/12/2024Cantor FitzgeraldReiterated RatingOverweight
1/2/2024Bank of AmericaBoost TargetBuy ➝ Buy$67.00 ➝ $80.00
12/18/2023Cantor FitzgeraldReiterated RatingOverweight
12/7/2023MizuhoInitiated CoverageBuy$69.00
11/7/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$58.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$70.00
8/9/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$58.00
5/9/2023888Reiterated RatingReiterates
4/18/2023TD CowenInitiated CoverageOutperform
4/17/2023Bank of AmericaBoost Target$63.00 ➝ $68.00
2/28/2023GuggenheimLower TargetBuy$66.00 ➝ $65.00
2/28/2023Needham & Company LLCReiterated RatingBuy$58.00
1/3/2023Needham & Company LLCBoost TargetBuy$52.00 ➝ $58.00
12/16/2022Leerink PartnersReiterated RatingOutperform$60.00
12/15/2022GuggenheimInitiated CoverageBuy$66.00
11/17/2022BTIG ResearchInitiated CoverageBuy$69.00
11/8/2022Cantor FitzgeraldBoost Target$55.00 ➝ $70.00
10/24/2022Bank of AmericaBoost Target$67.00
2/24/2022Needham & Company LLCReiterated RatingBuy$52.00
8/14/2020Needham & Company LLCReiterated RatingBuy$52.00
7/7/2020Bank of AmericaInitiated CoverageBuy$37.00
7/7/2020Jefferies Financial GroupInitiated CoverageBuy
7/7/2020Needham & Company LLCInitiated CoverageBuy$40.00
7/7/2020Cantor FitzgeraldInitiated CoverageOverweight$55.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.36 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 17 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 13 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 10 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 21 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 15 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 27 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 42 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 42 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Vaxcyte logo
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $86.53
Low: $86.25
High: $88.90

50 Day Range

MA: $98.70
Low: $85.75
High: $117.93

52 Week Range

Now: $86.53
Low: $53.83
High: $121.06

Volume

3,859,357 shs

Average Volume

922,601 shs

Market Capitalization

$10.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Vaxcyte?

The following sell-side analysts have issued stock ratings on Vaxcyte in the last twelve months: Bank of America Co., BTIG Research, Cantor Fitzgerald, Jefferies Financial Group Inc., Leerink Partners, Mizuho, Needham & Company LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for PCVX.

What is the current price target for Vaxcyte?

0 Wall Street analysts have set twelve-month price targets for Vaxcyte in the last year. Their average twelve-month price target is $145.71, suggesting a possible upside of 68.4%. Mizuho has the highest price target set, predicting PCVX will reach $163.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $129.00 for Vaxcyte in the next year.
View the latest price targets for PCVX.

What is the current consensus analyst rating for Vaxcyte?

Vaxcyte currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PCVX will outperform the market and that investors should add to their positions of Vaxcyte.
View the latest ratings for PCVX.

What other companies compete with Vaxcyte?

Other companies that are similar to Vaxcyte include Takeda Pharmaceutical, BioNTech, Teva Pharmaceutical Industries, BeiGene and Moderna. Learn More about companies similar to Vaxcyte.

How do I contact Vaxcyte's investor relations team?

Vaxcyte's physical mailing address is 353 HATCH DRIVE, FOSTER CITY CA, 94404. The company's listed phone number is 650-837-0111 and its investor relations email address is [email protected]. The official website for Vaxcyte is www.vaxcyte.com. Learn More about contacing Vaxcyte investor relations.